PIONEERING DIAGNOSTICS

intro image

Cystic Fibrosis & Antimicrobial Susceptibility Testing  (AST) Resources

On-Demand Webinars | P.A.C.E.® Credits Available

Trends in Bacterial Resistance and New Antibiotic Treatments for Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis

Chronic pulmonary infections in cystic fibrosis patients is an ongoing challenge. The emergence of multi-drug-resistant mucoid organisms, such as Pseudomonas aeruginosa, has further complicated these infections. At the end of the webinar, attendees should be able to:

  • List problem bacterial pathogens in CF patients and other current resistance trends in this population
  • Describe challenges with microbiological identification and susceptibility testing of CF pathogens
  • Identify new antibiotics that may play a role in the treatment of acute pulmonary exacerbations in patients with CF

Click Here To Access Webinar →

ETEST® Technology Overview: Supporting Antimicrobial Stewardship Initiatives

Due to exposure to antibiotics from an early age, individuals with CF often have drug-resistant organisms colonizing their respiratory tract. With CF patients living well into adulthood, preservation of antimicrobials is essential now more than ever. At the end of the webinar, attendees should be able to:

  • List the steps and requirements for testing & determining MICs 
  • Discuss how to support stewardship initiatives

Click Here To Access Webinar →

Downloads

ETEST Aerobic Reading Guide Antimicrobial Prescribing Booklet Enhanced Targeted Therapy for CF Patients Flyer Antimicrobial Stewardship Booklet


About Cystic Fibrosis 

Cystic Fibrosis (CF) affects approximately 70,000 children and adults worldwide and is the most frequently- occurring genetic life-shortening disease in Caucasians. While CF is a multi-organ disease, it is the decline in pulmonary function as a result of chronic infection that results in significant morbidity and mortality.

Non-fermenting Gram-negative pathogens such as Pseudomonas aeruginosa are responsible for chronic lung infections in over 80% of CF patients. Unfortunately, antibiotic resistance among CF pathogens continues to increase. Proper identification of the infecting organism and antimicrobial susceptibility testing are vital in selecting appropriate antibiotic therapy to successfully treat acute pulmonary exacerbations.

To learn more about bioMérieux’s well-established method for antimicrobial susceptibility testing, visit the product page.

bioMérieux, Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. CE Broker in the State of Florida may not accept P.A.C.E. credits.